Skip to content

Natural Orifice Transgastric Endoscopic Surgical Removal of the Gallbladder

Clinical Outcomes Trial of Laparoscopic Assisted Transgastric Endoscopic Cholecystectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01174069
Acronym
NOTESchole
Enrollment
25
Registered
2010-08-03
Start date
2007-05-31
Completion date
2015-10-31
Last updated
2019-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis

Keywords

NOTES, cholecystectomy, endoscopic

Brief summary

Hypothesis: Natural orifice transgastric cholecystectomy with laparoscopic assist will be feasible and have comparable complication rates as standard lap cholecystectomy. Patient benefits will include less pain and scaring.

Detailed description

In this study, we propose to use a surgical technique that eliminates the need for a 1.5-2.5 cm umbilical incision. A flexible endoscope will be inserted through the mouth and into the stomach. Using commercially available endoscopes, endoscopic instruments and accessories, a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. Two to three small laparoscopic trocars will be placed for laparoscopic instrument insertion to manipulate, retract and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. Once dissected free, the gall bladder will be removed through the stomach and out of the mouth. Commercially available endoscopic clips, sutures and/or tissue anchors will be used to close the gastrotomy; additionally, the gastrotomy will be tested for leaks and laparoscopically oversewn with suture as needed. Patients will be discharged per the standard of practice for a laparoscopic cholecystectomy. During the hospital stay severity of pain and use of pain medications will be recorded. Length of time spent in the recovery room and in the hospital will also be collected. Patients will return and be evaluated by their surgeon two weeks following their procedure. At this visit, any complications will be noted in the patient's medical record. Additionally at this visit and at the preoperative visit, patients will complete a standardized Quality of Life (QOL) assessment (i.e., SF-36) and perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record.

Interventions

PROCEDURENOTES assisted laparoscopic cholecystectomy

Surgical removal of the gallbladder using endoscopic instruments.

Sponsors

Northwestern University
CollaboratorOTHER
The Oregon Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Ability to undergo general anesthesia 2. Age \> 18 years of age and \< 80 years of age 3. Ability to give informed consent

Exclusion criteria

1. Acute cholecystitis 2. Body Mass Index (BMI) \> 40 3. Contraindicated for esophagogastroduodenoscopy (EGD) 4. Gallstones \> 2.5cm in diameter 5. Gall bladder more than 15cm in length on U/S 6. Presence of common duct stones 7. Presence of esophageal stricture 8. Altered gastric anatomy

Design outcomes

Primary

MeasureTime frameDescription
Postoperative pain30 daysperceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record.

Secondary

MeasureTime frameDescription
Perception of surgical outcome30 days post operativelystandardized Quality of Life (QOL) assessment (i.e., SF-36) form filled out by the patient.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026